Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach
International Journal of Clinical Endocrinology and Metabolism · 2017
DOI: 10.17352/ijcem.000024 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Endocrinology and Metabolism, 2017. Verfasst von IR Mohanty und 2 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Dipeptidyl peptidase-IV (DDP-IV) Inhibitors may represent single anti-diabetic drugs, the multiple actions of which may translate into demonstrable therapeutic benefi ts in diabetes.The marketed synthetic DPP-IV Inhibitors are expensive drugs and have been reported to cause unacceptable adverse effects such as pancreatitis, angioedema, thyroid and pancreatic cancers.In this scenario, research to identify DPP-IV Inhibitors from alternative sources is desirable. Aims and Objective:The study was designed to elucidate the DPP-IV Inhibitory activity of Berberine and Mangiferin, determine the binding sites and affi nity of Berberine and Mangiferin for DPP-IV enzyme using in silico studies and compare it to synthetic DPP-IV Inhibitor: Vildagliptin. Material and Methods:The crystal structure of human DPP IV (PDB Id: 2QT9) was downloaded from Protein Databank.Berberine and Mangiferin were computationally designed and screened through in silico docking studies against crystal structure of DPP-IV.Computational in silico studies were used to identify the sites as well as amino acid residues on DPP-IV enzyme to which these natural DPP-IV Inhibitors binds.
Results
The DPP-IV Inhibitory activity of Mangiferin was found to be comparable to synthetic marketed DPP-IV Inhibitors; Vildagliptin and Sitagliptin.Like Vildagliptin, Berberine and Mangiferin bind within the active site pocket (the 1st largest pocket) of DPP-IV enzyme whereas, Sitagliptin prefers to bind in the second largest pocket of DPP-IV enzyme.Berberine prefers to bind to the active site pocket of DPP-IV enzyme.Berberine binds very close to Glu205 and Glu206.As delineated using in silico binding energy results, Mangiferin, possess superior DPP-IV inhibitory activity as compared to Sitagliptin and Vildagliptin. Conclusion:In silico studies demonstrates that Berberine and Mangiferin possess signifi cant DPP-IV Inhibitory activity comparable to marketed synthetic DPP-IV Inhibitors.
Zitieren
APA
Mohanty, I., Kumar, S., & Rajesh, S. (2017). Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach. International Journal of Clinical Endocrinology and Metabolism. https://doi.org/10.17352/ijcem.000024
Vancouver
Mohanty I, Kumar S, Rajesh S. Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach. International Journal of Clinical Endocrinology and Metabolism. 2017. doi:10.17352/ijcem.000024
BibTeX
@article{Mohanty2017,
author = {Mohanty, IR and Kumar, S and Rajesh, Suman},
title = {Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach},
journal = {International Journal of Clinical Endocrinology and Metabolism},
year = {2017},
doi = {10.17352/ijcem.000024}
}
EUVIMED